Telmi-H Tablet

Hydrochlorothiazide + Telmisartan
12.5 mg + 40mg
Nepal Pharmaceuticals Pvt. Ltd.
Pack size 100's Pack
Dispensing mode
Source
Agent
Retail Price 18.00 NPR

Indications

Telmi-H Tablet is used for: Hypertension, Diabetic nephropathy

Adult Dose

Oral Hypertension Adult 1 tab (40-80 mg telmisartan/12.5-25 mg) once daily. Max: Telmisartan 160 mg & hydrochlorothiazide 25 mg daily. Hepatic Impairment Initiate therapy with low dose; titrate slowly; monitor

Child Dose

Renal Dose

Renal impairment Dose adjustment not necessary Hemodialysis patients are more susceptible to hypotension

Administration

May be taken with or without food.

Contra Indications

Severe hepatic impairment, biliary obstructive disorders. Pregnancy. Lactation.

Precautions

Hepatic insufficiency, biliary obstruction, renal impairment, renaly artery stenosis. Correct volume depletion before initiating treatment. Monitor serum potassium levels regularly, especially in elderly and renally-impaired patients. Lactation: discontinue drug or do not nurse

Pregnancy-Lactation

Pregnancy Category: C (1st trimester); D (2nd & 3rd trimesters)

Interactions

Lithium, kaliuretic diuretics, laxatives, corticosteroids, ACTH, amphotericin, carbenoxolone, penicillin G, salicylates, K-sparing diuretics, K supplements, K salt substitutes drugs that cause hyperkalaemia, digitalis glycosides, antiarrhythmic agents, drugs known to induce torsades de pointes, alcohol, barbiturates, narcotics, oral antidiabetics, insulin, anion-exchange resins, NSAIDs, nondepolarising skeletal muscle relaxants, pressor amines, allopurinol, Ca salts, beta-blockers, diazoxide, anticholinergics, amantadine, cytotoxics.

Adverse Effects

Side effects of Hydrochlorothiazide + Telmisartan : 1-10% Telmisartan Upper respiratory infection (7%),Urinary tract infection (1%),Back pain (3%),Diarrhea (3%),Myalgia (3%),Fatigue (1%),Sinusitis (3%),Peripheral edema (1%),Chest pain (1%),Hypertension (1%),Dyspepsia (1%),Headache (1%),Dizziness (1%),Pharyngitis (1%) Frequency Not Defined Hydrochlorothiazide Anorexia,Epigastric distress,Hypotension,Orthostatic hypotension,Photosensitivity,Anaphylaxis,Anemia,Confusion,Erythema multiforme,Stevens-Johnson syndrome,Exfoliative dermatitis including toxic epidermal necrolysis,Dizziness,Hypokalemia and/or hypomagnesemia,Hyperuricemia Potentially Fatal: Rarely angioedema, rash, pruritus and urticaria.

Mechanism of Action

Hydrochlorothiazide inhibits the reabsorption of Na and chloride in the distal tubules causing increased excretion of Na and water K and hydrogen ions. Telmisartan is a nonpeptide AT1 angiotensin II receptor antagonist. It exerts antihypertensive activity by preventing angiotensin II from binding to AT1 receptors thus inhibiting the vasoconstricting and aldosterone-secreting effects of angiotensin II.

Note

Telmi-H 12.5 mg + 40mg Tablet manufactured by Nepal Pharmaceuticals Pvt. Ltd.. Its generic name is Hydrochlorothiazide + Telmisartan. Telmi-H is availble in Nepal. Farmaco Nepal drug index information on Telmi-H Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.

Some other brands of Hydrochlorothiazide + Telmisartan :